Brief: Tricida Announces The Selection Of The Valor-CKD Trial For An Oral Presentation In The High-Impact Clinical Trials Session At ASN Kidney Week 2022
Oct 3 (Reuters) - Tricida Inc TCDA.O :
* TRICIDA ANNOUNCES THE SELECTION OF THE VALOR-CKD TRIAL FOR
AN
ORAL PRESENTATION IN THE HIGH-IMPACT CLINICAL TRIALS SESSION AT
ASN KIDNEY WEEK 2022
Source text for Eikon: ID:nBw8p49j1a
Further company coverage: TCDA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Tricida
See all newsBrief: Tricida Inc - On March 9, Company And Renibus Consummated Sale Of Certain Assets
Brief: Tricida Inc Receives Notice Of Delisting From Nasdaq
Brief: Tricida Inc Filed Voluntary Petition For Relief Under Chapter 11
Brief: Tricida - On December 19, 2022, Tricida Received An Additional Letter From Patheon Referencing The Purported Termination Notice From December 7, 2022
Brief: Tricida Inc - On December 6, Received Notice From Nasdaq That Co Is Not Been In Compliance With Minimum Bid Price Requirement - Filing